ALLK - Allakos Inc.

Allakos Inc.

825 Industrial Road
Suite 500
San Carlos, CA 94070
United States
650 597 5002
https://www.allakos.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 123

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Robert Alexander Ph.D.	CEO & Director	1.46M	N/A	1970
Dr. Adam L. Tomasi Ph.D.	Pres	1.11M	N/A	1970
Mr. Baird Radford III	Chief Financial Officer	708.26k	N/A	1970
Dr. Henrik Sandvad Rasmussen M.D., Ph.D.	Strategic Advisor	N/A	N/A	1959
Dr. Craig Paterson M.D.	Chief Medical Officer	N/A	N/A	1965
Dr. Brad Youngblood Ph.D.	Head of Research & Pre-Clinical Devel.	N/A	N/A	N/A
Ms. Mary Cromwell Ph.D.	SVP & Head of Technical Operations	N/A	N/A	N/A
Mr. Alan Chang	Director of Medical Affairs & Data Analytics	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. In addition, Allakos Inc. is conducting preclinical studies for AK007, which polarizes tumor-associated myeloid cells and promotes anti-tumor immunity. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Corporate governance

Allakos Inc.’s ISS governance QualityScore as of 1 June 2023 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.